Araştırma Makalesi

Composite Adverse Event Outcome in Pediatric Cancer Patients with Prolonged Febrile Neutropenia

Cilt: 6 Sayı: 2 1 Haziran 2016
  • Muhammad Matloob
PDF İndir
EN

Composite Adverse Event Outcome in Pediatric Cancer Patients with Prolonged Febrile Neutropenia

Abstract

Objective: Pediatric cancer patients with prolonged febrile neutropenia have increased risk for severe, recurrent or new bacterial and fungal infection. The aim of this study was to identify the risk factors associated with adverse outcomes in this group. Methods: We retrospective analyzed the clinical data of 135 hospitalizations of pediatric cancer patients with prolonged febrile neutropenia from a tertiary health care center of Pakistan. Results: The mean age of the study population was 7.3±4.1 years. There were 98 (72.6%) males and 37 (27.4%) females. Acute leukemia with 88 patients (65.2%) was the most common diagnosis followed by lymphomas 19 patients (14.1%) and solid tumors. Cause of febrile neutropenia was identified in only 58 (43.0%) patients, out of them blood stream infections were found in 22 cases (16.3%), pneumonia in 15 (11.1%), fungal infection in 13 (9.6%), infectious diarrheas in 5 (3.7%) and urinary tract infection (UTI) in 3 (2.2%) of cases. The composite adverse event outcome was observed in 28 (20.7%) of patients, with in-hospital mortality occurring in 7 (5.2%), Pediatric intensive care unit (PICU) admission occurring in 12 (8.9%) and inotropic support was required in 9 (6.7%). On logistic regression analysis AML (Adjusted odds ratio (AOR), 7.6; P<0.001), neutropenia <50/mm3 (AOR, 10.8; p<0.001), platelets count <50,000/mm3 (AOR, 5.2; p<0.001), BSI (AOR, 2.3; p 0.05) and fungal infection (AOR, 4.3; p<0.001) were found as independent risk factors for composite adverse event outcome in pediatric cancer patients with prolonged febrile neutropenia. Conclusions: AML, severe myelosuppression, blood stream infections and fungal infection were identifiable risk factors associated with development of adverse event outcome in pediatric cancer patients with prolonged febrile neutropenia. J Microbiol Infect Dis 2016;6(2): 69-73   

Keywords

Kaynakça

  1. 1. Ellis M. Febrile neutropenia evolving strategies. Ann NY Acad Sci 2008;1138:329-350.
  2. 2. Meckler G, Lindemulder S. Fever and neutropenia in pediatric patients with cancer. Emerg Med Clin North Am 2009;27:525- 544.
  3. 3. Walsh TJ RE, Groll AH, Gonzalez C, Pizzo P. Infectious complications in pediatric cancer patients. In: Pizzo PA, Poplack DG, eds. Principles & Practice of Pediatric Oncology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkens, 2005:1269- 1275.
  4. 4. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993;328:1323-1332.
  5. 5. Hughes WT, Armstrong D, Bodey GP, et al: 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34:730-751.
  6. 6. Ozer H, Armitage JO, Bennett CL, et al: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines-American Society of Clinical Oncology Growth and Factors Expert Panel. J Clin Oncol 2000;18:3558-3585.
  7. 7. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:427-431.
  8. 8. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control, 2008;36:309-332.

Ayrıntılar

Birincil Dil

Türkçe

Konular

Sağlık Kurumları Yönetimi

Bölüm

Araştırma Makalesi

Yazarlar

Muhammad Matloob Bu kişi benim

Yayımlanma Tarihi

1 Haziran 2016

Gönderilme Tarihi

16 Temmuz 2017

Kabul Tarihi

7 Ocak 2017

Yayımlandığı Sayı

Yıl 2016 Cilt: 6 Sayı: 2

Kaynak Göster

APA
Matloob, M. (2016). Composite Adverse Event Outcome in Pediatric Cancer Patients with Prolonged Febrile Neutropenia. Journal of Microbiology and Infectious Diseases, 6(2), 69-73. https://doi.org/10.5799/jmid.vi.328804
AMA
1.Matloob M. Composite Adverse Event Outcome in Pediatric Cancer Patients with Prolonged Febrile Neutropenia. Journal of Microbiology and Infectious Diseases. 2016;6(2):69-73. doi:10.5799/jmid.vi.328804
Chicago
Matloob, Muhammad. 2016. “Composite Adverse Event Outcome in Pediatric Cancer Patients with Prolonged Febrile Neutropenia”. Journal of Microbiology and Infectious Diseases 6 (2): 69-73. https://doi.org/10.5799/jmid.vi.328804.
EndNote
Matloob M (01 Haziran 2016) Composite Adverse Event Outcome in Pediatric Cancer Patients with Prolonged Febrile Neutropenia. Journal of Microbiology and Infectious Diseases 6 2 69–73.
IEEE
[1]M. Matloob, “Composite Adverse Event Outcome in Pediatric Cancer Patients with Prolonged Febrile Neutropenia”, Journal of Microbiology and Infectious Diseases, c. 6, sy 2, ss. 69–73, Haz. 2016, doi: 10.5799/jmid.vi.328804.
ISNAD
Matloob, Muhammad. “Composite Adverse Event Outcome in Pediatric Cancer Patients with Prolonged Febrile Neutropenia”. Journal of Microbiology and Infectious Diseases 6/2 (01 Haziran 2016): 69-73. https://doi.org/10.5799/jmid.vi.328804.
JAMA
1.Matloob M. Composite Adverse Event Outcome in Pediatric Cancer Patients with Prolonged Febrile Neutropenia. Journal of Microbiology and Infectious Diseases. 2016;6:69–73.
MLA
Matloob, Muhammad. “Composite Adverse Event Outcome in Pediatric Cancer Patients with Prolonged Febrile Neutropenia”. Journal of Microbiology and Infectious Diseases, c. 6, sy 2, Haziran 2016, ss. 69-73, doi:10.5799/jmid.vi.328804.
Vancouver
1.Muhammad Matloob. Composite Adverse Event Outcome in Pediatric Cancer Patients with Prolonged Febrile Neutropenia. Journal of Microbiology and Infectious Diseases. 01 Haziran 2016;6(2):69-73. doi:10.5799/jmid.vi.328804